Navigation Links
Halt Medical, Inc. Receives FDA Clearance
Date:6/15/2010

LIVERMORE, Calif., June 15 /PRNewswire/ -- Halt Medical, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the Halt 2000GI™ Electrosurgical System for soft tissue ablation using radiofrequency energy.  "This clearance to market is a major milestone for our customers, employees and investors," said Russ DeLonzor, President and Chief Operating Officer. 

Radiofrequency Ablation (RFA) with the Halt System is a very precise, minimally invasive procedure where a slender probe is inserted into the target tumor under ultrasound guidance.  Once in position, the system delivers a specified amount of energy to the tissue.  The heat generated in the process destroys the tumor, allowing it to be absorbed by the body.  RFA therapy is rapidly becoming the treatment of choice among surgeons seeking minimally invasive solutions for relieving debilitating symptoms caused by a variety of diseases such as tumors of the liver, breast, prostate, bone, and kidneys.   

"The Halt System offers broad advantages over surgery to doctors, their patients, and the healthcare system," according to Gordon Epstein, MD, Chief Technology Officer.  "With traditional surgical interventions, layers of healthy tissue are cut through to gain access to the tumor.  This leads to complications, significant pain, and long recovery times.  With RFA, patients typically go home the same day and are back to work much sooner.  The direct and indirect savings to the healthcare system as we replace radical surgery with minimally invasive procedures like Halt RFA will be in the billions of dollars."   

Halt Medical was founded in 2005 by Jeffrey M. Cohen, Dr. Bruce B. Lee, and Ed Calesa with the goal of developing an RFA system optimized for the treatment of symptomatic uterine fibroids.  The Halt Fibroid System was recently approved for use in Europe, and is currently being studied for this indication in the U.S.  "Receiving clearance by the FDA to market our general use ablation system represents a significant step towards our goal of extending the benefits of RFA to the treatment of uterine fibroids in the U.S.," said Mr. Cohen. 

Information about the Halt Fibroid Study and a list of clinical sites in the U.S. may be found at www.clinicaltrials.gov, study number NCT00874029.


'/>"/>
SOURCE Halt Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
4. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
5. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
6. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
7. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
8. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
9. Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidates Inscrybe Healthcare to Improve Care Order Processing
10. Apnex Medical, Inc. Raises Additional $14 Million
11. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: ... previously disclosed underwritten public offering of units with ... sole book-running manager, Roth Capital Partners acted as ... co-manager for the offering. "This financing ... proceeds, allowing us to continue advancing bremelanotide for ...
(Date:12/7/2016)... Md. , Dec. 7, 2016  Northwest ... or the "Company"), a biotechnology company developing DCVax® ... announced that the Nasdaq Staff has not accepted ... of Listing Rules previously reported, and the Company ... withdraw the Company,s common stock from listing on ...
(Date:12/7/2016)... , December 7, 2016 ... Trial Management System (CTMS) Market, by Components (Software, ... Site), End-users (Pharmaceutical and Biotechnology Companies, Clinical Research ... Share, Size and Forecast to 2022", published by ... system (CTMS) market is expected to grow at ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... now promoting to the US market its advanced highly customizable contact technology solutions. ... ODU TURNTAC®. These advanced technologies are ideal for a wide range of applications ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers Insurance ... residents in the Sacramento/Folsom region, is initiating a charity event to raise support ... Choice Another Chance treatment center in Sacramento works to provide area teens and ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... A. Kevin ... owners and families throughout the Five Boroughs, is launching a charity drive to raise ... to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the ... and Your Health on Voice of America, declared on her radio program in November ... the fact that when these bullies attack leaders in corporate America, they are trying ...
Breaking Medicine News(10 mins):